Plenary Session - inactive due to federal service - podcast cover

Plenary Session - inactive due to federal service

Vinay Prasad, MD MPHsoundcloud.com
Dr Prasad currently serves as the Director of the Center for Biologics Evaluation and Resesarch (CBER) at the US FDA. The audio on this platform were posted before my FDA employment and do not necessarily represent the views of the FDA or the United States. This site will be inactive during my federal service. A podcast on medicine, oncology, & health policy. Host: Vinay Prasad, MD MPH from University of California San Francisco. Tweet your feedback to @Plenary_Session or e-mail [email protected]

Episodes

2.28 Trastuzumab in Later Lines of Therapy for HER2+ Breast Cancer, Kaplan-Meier Curves, & Patreon

We're back in Plenary Session HQ! We have multiple topics for you this week. We cover the use of trastuzumab in later lines of therapy for HER2+ metastatic breast cancer, we take a listener question on Kaplan-Meier curves, and we talk a little about Patreon. Malignant: www.amazon.com/Malignant-Policy-Evidence-People-Cancer/dp/1421437635 Back us on Patreon! www.patreon.com/plenarysession

Dec 20, 20191 hr 4 min

2.26 Questions of the Week: Hematology/Oncology, USMLE Step 2 CK, & a bonus Hematology/Oncology

This is the last week of pre-recorded episodes -- we'll be back next week with a fresh, hard-hitting monologue. In the meantime, we have three questions of the week for you. Two are inspired by the hematology/oncology boards and are presented by Dr. Sven Olson. Between the two, we have one from Ian Straehely that's inspired by the USMLE Step 2 CK. Back us on Patreon! www.patreon.com/plenarysession

Dec 09, 201940 min

2.25 Questions of the Week: Hematology/Oncology, the USMLE Step 2 CK, & One From a Med Student

Our host is still out of town, but don't worry -- we have some questions of the week to tide you over. The first is inspired by the hematology/oncology boards, presented by Dr. Sven Olson; the second is inspired by the USMLE Step 2 CK, presented by Ian Straehley; and the third is from Audrey Tran, inspired by her experiences as a med student. Back us on Patreon! www.patreon.com/plenarysession

Dec 02, 201947 min

2.24 Questions of the Week: the USMLE Step 2 CK, Hematology/Oncology, & One From a Med Student

This week our host is still in Australia, but we have some questions of the week saved for you! The first is inspired by the USMLE Step 2 CK, presented by Ian Straehley; the second is inspired by the hematology/oncology boards, presented by Dr. Sven Olson; and the third is from Audrey Tran, inspired by her experiences as a med student. Back us on Patreon! www.patreon.com/plenarysession

Nov 26, 201938 min

2.23 Question of the Week & Ethics and Inefficiencies of Clinical Trials with Dr. Jonathan Kimmelman

First up this week is Question of the Week inspired by the Hematology/Oncology boards, with Dr. Sven Olson. No monologue on current trials this week because our host is still in Australia, so we conclude the episode with an interview with Dr. Jonathan Kimmelman of McGill University on his extensive work in research ethics, studying the most important issue in cancer medicine today: the risk-benefit of clinical trials and how best to spare patients from the burdens of creating a new drug. Review ...

Nov 20, 201958 min

2.22 Question of the Week & EMR, Talking to Patients, and Being a Doctor with Dr. Robert Hirschtick

This week we have a question of the week from Ian Straehley, inspired by the USMLE Step 2 CK, as well as an interview with Dr. Robert Hirschtick of Northwestern University on what it means to be a doctor, how you should think as a physician, and his many popular pieces published in journals like JAMA. "Copy-and-Paste": doi.org/10.1001/jama.295.20.2335 "Extremities": doi.org/10.1001/jama.300.10.1125 "The Quick Physical Exam": doi.org/10.1001/jama.2016.8182 Robiewon on YouTube: www.youtube.com/cha...

Nov 15, 201956 min

2.21 Aiming for the Hard Targets & Harm From Screening and Overdiagnosis with Dr. H Gilbert Welch

We begin this week's episode by addressing a listener's feedback to our discussion of smoldering multiple myeloma. We then expand on our critique of 'going after the soft targets' (criticizing studies that fall apart with little resistance) by elucidating how to identify and go after hard targets and why it's so important that you do. Finally, we launch into an interview with Dr. H Gilbert Welch that explores his tremendous body of work on the preventable harm that comes from too generous a hand...

Nov 08, 20192 hr 14 min

2.20 "Courageous Skeptics", Lenalidomide, QOTW, and a Political Conversation with Dr. Andy Saultz

We begin this week's episode with a thoughtful discussion of the internet's "courageous skeptics". Then, after lamenting the way in which the recent study "Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma" was conducted, we end with an interview with Dr. Andy Saultz on his ongoing campaign for Oregon state representative. We break up the interview with a couple Hem/Onc boards questions of the week from Dr. Emerson Chen. Lenalidomide in Smoldering Multiple Myelom...

Nov 01, 20192 hr 36 min

2.19 Remembering Dr. Bernard Fisher & Self-Diagnosis with Dr. Mark Lewis

This week we give a short monologue on the late Dr. Bernard Fisher's legacy in the field of oncology, and then dive into a far-ranging interview with Dr. Mark Lewis of Intermountain Healthcare on his career, his family, and diagnosing himself with MEN1 syndrome. Dr. Fisher's obituary in the New York Times: https://www.nytimes.com/2019/10/19/science/dr-bernard-fisher-dead.html Back us on Patreon! www.patreon.com/plenarysession

Oct 25, 20192 hr 13 min

2.18 Questions of the Week, Talking About Toxicity, ASCO Guidelines Authors' COI with Dr. Eitan Amir

This week we begin with a critique of the recent perspective article in the New England Journal of Medicine, titled "Talking about Toxicity — 'What We’ve Got Here Is a Failure to Communicate'". After that we interview Dr. Eitan Amir on his paper on undisclosed conflicts of interest among authors of ASCO guidelines. Interspersed between segments of the interview, we invite guest Dr. Sven Olson on to offer a correction to a recent Hem/Onc boards question of the week on Lynch Syndrome (original que...

Oct 18, 20191 hr 17 min

2.17 Questions of the Week, BEACON, & Use of Subacuate Rehab with Dr. Jonathan Yeh

We start this week's episode with a quick breakdown of why the recent BEACON trial is "the worst trial" host VP has ever read. After that, we have two questions of the week: one from medical student Audrey Tran, and one inspired by the Hem/Onc boards from Dr. Sven Olson. We end with an interview with Dr. Jonathan Yeh of Johns Hopkins University School of Medicine on his recent paper: "Has There Been a Shift in Use of Subacute Rehabilitation Instead of Hospice Referral Since Immunotherapy Has Bec...

Oct 08, 20191 hr 22 min

2.16 FLAURA & What Truly Matters in the Career of an Academic Physician with Dr. Vinay Prasad

This week we break down the limitations of the recent FLAURA trial and then we're back in the Plenary Session Mobile Command Unit! We have a special guest host, Dr. Christopher Booth of Queen's University in Kingston, Ontario, Canada. He and Dr. Bishal Gyawali, also of Queen's University, conduct a reverse interview with our usual host, Dr. Vinay Prasad of Oregon Health & Science University, on his career, the formation of Plenary Session, and what truly matters in the career of an academic ...

Oct 02, 20191 hr 38 min

2.15 Bonus! The Value of Progression-Free Survival as a Treatment Endpoint with Dr. Michael Raphael

This BONUS episode is an interview with Dr. Michael Raphael of Sunnybrook Health Sciences Centre in Toronto, Ontario on his new paper out today in JAMA Oncology: "The value of progression-free survival as a treatment endpoint among patients with advanced cancer: a systematic review and qualitative assessment of the literature". Value of PFS: https://jamanetwork.com/journals/jamaoncology/article-abstract/2751879 Back us on Patreon! www.patreon.com/plenarysession

Sep 26, 201935 min

2.14 Questions of the Week & Qualifications of a Fellowship Applicant with Dr. Jeremy Cetnar

This week we sit down with Dr. Jeremy Cetnar, director of the Oregon Health & Science University Hematology & Oncology Fellowship Program. In this far-ranging interview, we discuss what he is looking for when reviewing applications to the fellowship program. We also have two questions of the week: one from Dr. Derrick Tao, inspired by the MKSAP; and one from Dr. Sven Olson on hematology and oncology. Tweetorials: http://doi.org/10.1056/NEJMp1906790 Back us on Patreon! www.patreon.com/ple...

Sep 24, 20191 hr 41 min

2.13 BONUS! RCTs Supporting Approvals of Cancer Drugs by EMA with Dr. Huseyin Naci

On this week's BONUS episode, we sit down with Dr. Huseyin Naci, Assistant Professor of Health Policy at the London School of Economics, to discuss his new paper that came out Wednesday (producer's edit: not "yesterday" as said in the podcast - apologies for the delay!) in the British Medical Journal. The paper's titled "Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014-16: cross sectional a...

Sep 20, 201940 min

2.12 Questions of the Week, Ethics of RCTs, & Transmission and Medical Overuse with Dr. Dan Morgan

We begin this week's episode by revisiting last week's topic on the ethics of randomized controlled trials (RCTs) to address some of the controversy stirred up by our episode. We transition from there to an interview with Dr. Dan Morgan of the University of Maryland School of Medicine on hospital transmission and medical overuse. We have two questions of the week, as well -- one from Ian Straehley, inspired by the USMLE Step 2 CK; and one from Audrey Tran, inspired by the life of a medical stude...

Sep 17, 20191 hr 38 min

2.11 Questions of the Week, When RCTs are Necessary, & AYA Oncology with Dr. Adam Duvall

After a hiatus from our segment on reviewing recent trials, we return to discuss the need for randomized controlled trials (RCTs). In the wake of the 2019 World Conference on Lung Cancer, we focus on whether a phase III trial of selpercatinib (LOXO-292) in RET rearranged lung cancer is feasible, practical, and ethical. We also have two questions of the week in this episode -- one from Dr. Derrick Tao, inspired by the MKSAP; and one from Dr. Sven Olson on hematology and oncology -- as well as an ...

Sep 12, 20191 hr 41 min

2.09 Questions of the Week & Informed Consent in Clinical Trials with Dr. Lynn Jansen

We start this week with two Questions of the Week: the first is from Ian Straehley on the USMLE Step 2 CK, and the second is from Dr. Sven Olson on hematology/oncology. We end with an interview with Dr. Lynn Jansen of OHSU on the therapeutic misconception, optimism bias, and a deep discussion of the ethics of consenting patients for enrollment in early-phase clinical research trials. Back us on Patreon! www.patreon.com/plenarysession

Aug 28, 20191 hr 20 min

2.07 Translational Research & Physical Examination Pet Peeves with Dr. Adam Cifu

We start this week's episode with a Question of the Week from medical student Audrey Tran on translational research and medical student training. Afterwards, we have an in-depth interview with Dr. Adam Cifu of the University of Chicago on his recent publication: "Physical Examination Pet Peeves". Pet Peeves: doi.org/10.4300/JGME-D-18-01063.1 Back us on Patreon! www.patreon.com/plenarysession

Aug 16, 20191 hr 17 min

2.06 Heart Failure, Choosing a Specialty, & the Bayesian Approach with Dr. Frank Harrell

We're back with more questions of the week! Our first question, from Ian Straehley, is inspired by the USMLE Step 2 CK; our second question, from Audrey Tran, is on deciding on a medical specialty. We end the episode with an interview with Dr. Frank Harrell of Vanderbilt University on the Bayesian approach to statistical thinking. Back us on Patreon! www.patreon.com/plenarysession

Aug 06, 20191 hr 50 min

2.05 Reup! Cancer Screening 101 with Dr. Adam Obley

In this REUP episode, we replay a section of our interview with Dr. Adam Obley of OHSU: a primer on cancer screening. This audio was first aired on episode 2.03. Not So Silver Lining: doi.org/10.1001/archinternmed.2011.73 Mammography Screening: Truth, Lies and Controversy: www.crcpress.com/Mammography-Screening-Truth-Lies-and-Controversy/Gotzsche/p/book/9781846195853 Back us on Patreon! www.patreon.com/plenarysession

Jul 31, 20191 hr 13 min

2.04 Reup! Tumor-Treating Fields for Glioblastoma with Dr. Michael Hayes

In this REUP episode, we replay a section of our interview with Dr. Michael Hayes of Kaiser Permanente. This audio was first aired on episode 2.01. The interview is on the relationship between conflict of interest and editorial stance on tumor-treating fields for glioblastoma multiforme. TTF: doi.org/10.1016/j.jcpo.2019.100189 Back us on Patreon! www.patreon.com/plenarysession

Jul 30, 201936 min

2.03 Dr. Charles Moertel and the Modern Oncologist & Cancer Screening 101 with Dr. Adam Obley

This week we launch a new segment on Plenary Session: Question of the Week! We invite Dr. Sven Olson on to ask a sample hematology/oncology boards question and we invite Audrey Tran on to ask a question from a medical student. Before that, we talk about the legacy of Dr. Charles Moertel and how modern oncologists, in contrast, will be remembered. We end the episode with an interview with Dr. Adam Obley of OHSU -- his fourth appearance on the podcast! -- on cancer screening. Dr. Moertel's obituar...

Jul 23, 20192 hr 6 min

2.01 Selinexor, ECHELON-2, Parachutes, Tumor-Treating Fields, & MedTwitter

Welcome to season 2! We're starting this season off with a little bit of everything: a critique of the FDA's accelerated approval of selinexor for penta-refractory multiple myeloma; an interview with Dr. John Reneau of Ohio State University on ECHELON-2 (brentuximab vedotin in t-cell lymphomas); an interview with Dr. Michael Hayes of Kaiser Permanente on parachutes in medicine plus the relationship between conflict of interest and editorial stance on tumor-treating fields for glioblastoma multif...

Jul 12, 20192 hr 38 min

1.68 Voxeletor with Dr. Olson & Humanizing Cancer, Defining Cancer, and more with Dr. David Steensma

We begin this week's episode by breaking down the recent phase III trial on voxeletor in sickle cell disease with Dr. Sven Olson of OHSU. Next, we feature guest Dr. David Steensma of the Dana-Farber Cancer Institute in a far-reaching interview on being well-read, running a small lab, humanizing cancer, learning from our past use of erythropoiesis-stimulating agents, understanding the headache of contract research organizations, defining cancer, and more! Voxeletor in Sickle Cell: doi.org/10.1056...

Jul 05, 20192 hr 6 min

1.67 MONALEESA-7 and the Cost of Cancer Drugs with Dr. Stacie Dusetzina

This week we begin the episode by discussing MONALEESA-7 and why ribociclib has been shown to increase overall survival while palbociclib has not. We finish the episode with an in-depth interview with Dr. Stacie Dusetzina of Vanderbilt University on her work in pharmacoeconomics, specifically we discuss her work on the market value of cancer drugs. MONALEESA-7: doi.org/10.1056/NEJMoa1903765 Free drug samples are a marketing tool: doi.org/10.2105/AJPH.2007.114249 Back us on Patreon! www.patreon.c...

Jun 27, 20192 hr 20 min
For the best experience, listen in Metacast app for iOS or Android
Open in Metacast